Qinecsa Solutions, a provider of technology pharmacovigilance solutions, has acquired Insife ApS (Insife), a Danish-based software, technology, and consultancy firm specializing in developing pharmacovigilance platforms. 
 
Qinecsa offers solutions that integrate technology and scientific expertise through platforms like Reportum and CVW that allow customers to capture, manage, and evaluate drug safety data throughout the drug life cycle.
 
Insife’s HALOPV platform is considered a safety database with multivigilance capabilities and covers end-to-end management of PV processes. HALOPV is available as an enterprise-grade technology, as well as in a multi-tenant SaaS offering for cost-effective uses. Insife’s global regulatory intelligence for pharmacovigilance (GRIP) club is a combination of technology, multi-sourced intelligence and networking, specifically for pharmacovigilance professionals involved in identifying, assessing and implementing requirements.
 
Bringing together Qinecsa and Insife’s understanding of the pharmaceutical industry and regulatory environment aims to offer enhanced pharmacovigilance services and technologies to support pharmaceutical companies and regulatory agencies worldwide.
 
John Gillie, CEO of Qinecsa Solutions, said, “We are thrilled to welcome Insife into the Qinecsa family. This marks a significant milestone and is a natural fit, reinforcing our position as a unique pharmacovigilance provider. By integrating Insife’s cutting-edge automation technology, specialized knowledge, and consultancy services into our offerings, we are poised to deliver even greater value and support to our customers globally.”
 
“We are excited about the opportunities that lie ahead as an entity within Qinecsa Solutions,” said Martin Holm-Petersen, CEO of Insife. “Joining forces with Qinecsa is a strategic move for the company, its people, and customers. We will leverage the platform to expand our global footprint and better support our clients with HALOPV in combination with Qinecsa’s best-of-breed technology solutions and services for all areas and life cycles of drugs. We will be able to underline our position as the number one technology provider for pharmacovigilance, expand our reach and capabilities, while driving positive outcomes for the pharmaceutical industry.”